Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jul 13, 2018--The “Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights” report has been added to ResearchAndMarkets.com’s offering.
Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems. Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson’s.
The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease.
The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well.
Companies Mentioned:3M New Ventures 4P Therapeutics 5AM Ventures Abbott ApoPharma Araclon Biotech ArmaGen Armistice Capital Arrien Pharmaceuticals Asceneuron AstraZeneca Atlas Venture Auckland City Hospital Avanir Pharmaceuticals Avant Diagnostics Axovant Sciences AZTherapies Azur Pharma Babraham Research Campus Bayer Ben Franklin Technology Partners BenevolentAI Bertin Bioreagent BIAL BioAdvance BioArctic BioElectron Technology Biogen BioReference Laboratories Biotie Therapeutics
Key Topics Covered:
2. Executive Summary
4. Pipeline Review: Marketed And Development Drugs
5. Parkinson’s Disease: UNMET Need Analysis
6. Drug Profiles: Phase III Molecules
7. Company Competitiveness Analysis
8. Mergers And Acquisitions
9. Kol Analysis
10. Funding And Investment Analysis
11. Survey Analysis
12. Appendix 1: Tabulated Data
13. Appendix 2: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/research/pbs2hb/parkinsons?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180713005092/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 07/13/2018 04:59 AM/DISC: 07/13/2018 04:59 AM